ATP12A and gastroesophageal reflux disease: Since their introduction two decades ago, proton pump inhibitors (PPIs) became the mainstay in gastro esophageal reflux (GERD), peptic ulcer disease (PUD), persistent non-steroidal anti-inflammatory drug (NSAID) treatment and generalized dyspepsia (heartburn) [1–3].